Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan; 107(1):28-35; quiz 36.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.